International Journal of Endocrinology / 2019 / Article / Tab 5

Research Article

Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism

Table 5

Treatments administered to patients with GEP-NETs.
(a)

Gastric, (%)Duodenum, (%)Rectum, (%)

Endoscopic therapy ()21 (52.5)4 (10.0)15 (37.5)

(b)

NET G1NET G2NEC

Surgical therapy ()$125 out of 155 (80.6)48 out of 60 (80.0)18 out of 25 (72.0)0.607
Surgery of metastases ()$22 out of 121 (18.2)9 out of 44 (20.5)8 out of 18 (44.4)0.055

Liver ablative therapy
TAE ()$7 out of 131 (5.3)3 out of 49 (6.1)0 out of 19 (0.0)0.781
RFA ()$3 out of 61 (4.9)1 out of 27 (3.7)0 out of 13 (0.0)>0.999

Systemic therapies
Somatostatin analogues ()$31 out of 152 (20.4)32 out of 54 (59.3)8 out of 25 (32.0)<0.001
Interferon ()$+SSAs3 out of 152 (2.0)1 out of 55 (1.8)0 out of 24 (0.0)>0.999
Target therapies ()$2 out of 153 (1.3)2 out of 53 (3.8)3 out of 25 (12.0)0.020
PRRNT ()$3 out of 150 (2.0)6 out of 55 (10.9)0 out of 25 (0.0)0.021
Chemotherapy ()$3 out of 157 (1.9)6 out of 60 (10.0)11 out of 27 (40.7)<0.001

$Number of cases with information. TAE = transhepatic arterial embolization; RFA = radiofrequency ablation; PRRNT: peptide receptor radionuclide therapy. Sunitinib; 177Lu-THERA.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.